Modulating dendritic cells (DC) from immunogenic to tolerogenic responses: A novel mechanism of AZA/6-MP

Journal of Neuroimmunology

Volumn 218, Issue 1-2, 2010, Pages 28-35

  Aldinucci, Alessandra ^a   Biagioli, Tiziana ^a   Manuelli, Cinzia ^a   Repice, Anna Maria ^a   Massacesi, Luca ^a   Ballerini, Clara ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Azathioprine; Dendritic cells; Tolerance

Indexed keywords

AZATHIOPRINE; CHEMOKINE RECEPTOR CCR7; INTERLEUKIN 10; INTERLEUKIN 23; MERCAPTOPURINE;

ADULT; ARTICLE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL FUNCTION; CELL POLARITY; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG MECHANISM; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IN VITRO STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; T LYMPHOCYTE;

ADULT; AZATHIOPRINE; CELL DIFFERENTIATION; CELLS, CULTURED; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE CULTURE TEST, MIXED; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECEPTORS, CCR7;

EID: 73149084853     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2009.11.001     Document Type: Article

References (37)

1. Abdou N.I., Zweiman B., and Casella S.R. Effects of azathioprine therapy on bone marrow-dependent and thymus-dependent cells in man. Clin. Exp. Immunol. 13 (1973) 55-64
2. Aerts-Toegaert C., Heirman C., Tuyaerts S., Corthals J., Aerts J.L., Bonehill A., Thielemans K., and Breckpot K. CD83 expression on dendritic cells and T cells: correlation with effective immune responses. Eur. J. Immunol. 37 3 (2007) 686-695
3. Andreone P.A., Olivari M.T., Elick B., Arentzen C.E., Sibley R.K., Bolman R.M., Simmons R.L., and Ring W.S. Reduction of infectious complications following heart transplantation with triple-drug immunotherapy. J. Heart Transplant. 5 1 (1986) 13-19
4. Bailey S.L., Schreiner B., McMahon E.J., and Miller S.D. CNS myeloid DCs presenting endogenous myelin peptides 'preferentially' polarize CD4+ T(H)-17 cells in relapsing EAE. Nat. Immunol. 8 2 (2007) 172-180
5. Bouhnik Y., Lémann M., Mary J.Y., Scemama G., Taï R., Matuchansky C., Modigliani R., and Rambaud J.C. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 347 8996 (1996) 215-219
6. British and Dutch Multiple Sclerosis Azathioprine Trial Group. Double-masked trial of azathioprine in multiple sclerosis. Lancet 2 8604 (1988) 179-183
7. Bryant J., Clegg A., and Milne R. Systematic review of immunomodulatory drugs for the treatment of people with multiple sclerosis: is there good quality evidence on effectiveness and cost?. J. Neurol. Neurosurg. Psychiatry 70 5 (2001) 574-579
8. Chan G.L., Erdmann G.R., Gruber S.A., Matas A.J., and Canafax D.M. Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients. J. Clin. Pharmacol. 30 4 (1990) 358-363
9. Christensen E., Neuberger J., Crowe J., Altman D.G., Popper H., Portmann B., Doniach D., Ranek L., Tygstrup N., and Williams R. Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Final results of an international trial. Gastroenterology 89 5 (1985) 1084-1091
10. De Silva M., and Hazleman B.L. Long-term azathioprine in rheumatoid arthritis: a double-blind study. Ann. Rheum. Dis. 40 6 (1981) 560-563
11. Fraser A.G., Orchard T.R., Robinson E.M., and Jewell D.P. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment. Pharmacol. Ther. 16 7 (2002) 1225-1232
12. Ginzler E., Sharon E., Diamond H., and Kaplan D. Long-term maintenance therapy with azathioprine in systemic lupus erythematosus. Arthritis Rheum. 18 1 (1975) 27-34
13. Hawiger D., Inaba K., Dorsett Y., Guo M., Mahnke K., Rivera M., Ravetch J.V., Steinman R.M., and Nussenzweig M.C. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 194 6 (2001) 769-779
14. Ifergan I., Kébir H., Bernard M., Wosik K., Dodelet-Devillers A., Cayrol R., Arbour N., and Prat A. The blood-brain barrier induces differentiation of migrating monocytes into Th17-polarizing dendritic cells. Brain 131 Pt 3 (2008) 785-799
15. Kuwano Y., Prazma C.M., Yazawa N., Watanabe R., Ishiura N., Kumanogoh A., Okochi H., Tamaki K., Fujimoto M., and Tedder T.F. CD83 influences cell-surface MHC class II expression on B cells and other antigen-presenting cells. Int. Immunol. 19 8 (2007) 977-992
16. Langrish C.L., McKenzie B.S., Wilson N.J., de Waal Malefyt R., Kastelein R.A., and Cua D.J. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol. Rev. 202 (2004) 96-105
17. Lechmann M., Berchtold S., Hauber J., and Steinkasserer A. CD83 on dendritic cells: more than just a marker for maturation. Trends Immunol. 23 6 (2002) 273-275
18. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur. J. Clin. Pharmacol. 43 (1992) 329-335
19. Liu W., Ouyang X., Yang J., Liu J., Li Q., Gu Y., Fukata M., Lin T., He J.C., Abreu M., Unkeless J.C., Mayer L., and Xiong H. AP-1 activated by toll-like receptors regulates expression of IL-23 p19. J. Biol. Chem. 284 36 (2009) 24006-24016
20. Maltzman J.S., and Koretzky G.A. Azathioprine: old drug, new actions. J. Clin. Invest. 111 8 (2003) 1133-1145
21. Massacesi L., Parigi A., Barilaro A., Repice A.M., Pellicanò G., Konze A., Siracusa G., Taiuti R., and Amaducci L. Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging. Arch. Neurol. 62 12 (2005) 1843-1847
22. McGeown M.G., Douglas J.F., Donaldson R.A., Hill C.M., Kennedy J.A., Loughridge W.G., and Middleton D. Ten-year results of renal transplantation with azathioprine and prednisolone as only immunosuppression. Lancet 1 8592 (1988) 983-985
23. McMahon E.J., Bailey S.L., Castenada C.V., Waldner H., and Miller S.D. Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat. Med. 11 3 (2005) 335-339
24. Miller S.D., McMahon E.J., Schreiner B., and Bailey S.L. Antigen presentation in the CNS by myeloid dendritic cells drives progression of relapsing experimental autoimmune encephalomyelitis. Ann. N. Y. Acad. Sci. 1103 (2007) 179-191
25. Poppe D., Tiede I., Fritz G., Becker C., Bartsch B., Wirtz S., Strand D., Tanaka S., Galle P.R., Bustelo X.R., and Neurath M.F. Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J. Immunol. 176 1 (2006) 640-651
26. Prazma C.M., and Tedder T.F. Dendritic cell CD83: a therapeutic target or innocent bystander?. Immunol. Lett. 115 1 (2008) 1-8
27. Riol-Blanco L., Sánchez-Sánchez N., Torres A., Tejedor A., Narumiya S., Corbí A.L., Sánchez-Mateos P., and Rodríguez-Fernández J.L. The chemokine receptor CCR7 activates in dendritic cells two signaling modules that independently regulate chemotaxis and migratory speed. J. Immunol. 174 7 (2005) 4070-4080
28. Röllinghoff M., Schrader J., and Wagner H. Effect of azathioprine and cytosine arabinoside on humoral and cellular immunity in vitro. Clin. Exp. Immunol. 15 (1973) 261-269
29. Sallusto F., Cella M., Danieli C., and Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J. Exp. Med. 182 2 (1995) 389-400
30. Sánchez-Sánchez N., Riol-Blanco L., and Rodríguez-Fernández J.L. The multiple personalities of the chemokine receptor CCR7 in dendritic cells. J. Immunol. 176 9 (2006) 5153-5159
31. Serafini B., Rosicarelli B., Magliozzi R., Stigliano E., Capello E., Mancardi G.L., and Aloisi F. Dendritic cells in multiple sclerosis lesions: maturation stage, myelin uptake, and interaction with proliferating T cells. J. Neuropathol. Exp. Neurol. 65 2 (2006) 124-141
32. Stasiolek M., Bayas A., Kruse N., Wieczarkowiecz A., Toyka K.V., Gold R., and Selmaj K. Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis. Brain 129 Pt 5 (2006) 1293-1305
33. Tiede I., Fritz G., Strand S., Poppe D., Dvorsky R., Strand D., Lehr H.A., Wirtz S., Becker C., Atreya R., Mudter J., Hildner K., Bartsch B., Holtmann M., Blumberg R., Walczak H., Iven H., Galle P.R., Ahmadian M.R., and Neurath M.F. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J. Clin. Invest. 111 8 (2003) 1133-1145
34. Vaknin-Dembinsky A., Balashov K., and Weiner H.L. IL-23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL-23 by antisense oligos increases dendritic cell IL-10 production. J. Immunol. 176 12 (2006) 7768-7774 (Erratum in: J Immunol. 2006 177(3), 2025)
35. Vergelli M., Hemmer B., Utz U., Vogt A., Kalbus M., Tranquill L., Conlon P., Ling N., Steinman L., McFarland H.F., and Martin R. Differential activation of human autoreactive T cell clones by altered peptide ligands derived from myelin basic protein peptide (87-99). Eur. J. Immunol. 26 11 (1996) 2624-2634
36. Yudkin P.L., Ellison G.W., Ghezzi A., Goodkin D.E., Hughes R.A., McPherson K., Mertin J., and Milanese C. Overview of azathioprine treatment in multiple sclerosis. Lancet 338 8774 (1991) 1051-1055
37. Zhou L.J., Schwarting R., Smith H.M., and Tedder T.F. A novel cell-surface molecule expressed by human interdigitating reticulum cells, Langerhans cells, and activated lymphocytes is a new member of the Ig superfamily. J. Immunol. 149 2 (1992) 735-742